Research shows 60% of missense mutations destabilize proteins, linking protein folding to genetic diseases, including ...

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...

MPs call for tougher regulation on engineered stone linked to silicosis, saying new HSE guidance doesn't go far enough ...

Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...

Labour MPs rejected a Tory demand for a new national inquiry into grooming gangs. The House of Commons opposed a call, ...

On a recent visit to Washington DC, Ho sat down with GEN Editorial Director Kevin Davies, PhD, to discuss Denali’s progress ...

MPs vote to reject national grooming gangs inquiry in Commons ...

A man who has won some of football's highest honours has spoke of his fears he could develop dementia due to heading the ball ...

The Communicable Diseases Agency has five areas of responsibility, including prevention and response. Read more at ...

Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...

An update from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) is now available.

Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.